China’s NMPA rejects fruquintinib for second line gastric cancer

2 September 2024

Chinese biopharma Hutchmed (HKEX:13) on Friday announced that it has voluntarily withdrawn its supplemental New Drug Application (NDA) in China for fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric or gastroesophageal junction adenocarcinoma.

The company said it will evaluate a new route forward. Following an additional internal review of the current data package, in light of recent discussions with the National Medical Products Administration of China (NMPA), Hutchmed has determined that the submission is unlikely to support an approval in China at this time.

Fruquintinib is already approved in China, where US pharma major Eli Lilly (NYSE: LLY) has co-marketing rights, as Elunate for third-line colorectal cancer. It is also authorized under the trade name Fruzaqla in the USA, where Hutchmed sold rights to Takeda (TYO: 4502) for $400 million, citing tough market conditions and a focus on its most profitable activities.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology